Immunovant, Inc. Common Stock (IMVT) Stock
Key stats
- Market cap
- $7.67B
- Price / Earnings ratio
- -14.5x
- EPS (TTM)
- -$2.56
- Volume
- Loading
- 52-week high
- $45.42
- 52-week low
- $21.86
Source: third-party data provider, as of November 13, 2026
Compare with IMVT
Recent news

IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
IMVT

IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
IMVT

IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
IMVT

Immunovant Q1 Earnings Call Highlights
Immunovant Q1 Earnings Call Highlights
IMVT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 70.54
- MACD 12/26/9
- 0.55
- EMA 9 of MACD
- -0.65
- MACD histogram
- 1.20
- SMA 50
- $32.83
- Price above SMA 50
- EMA 50
- $32.66
- Price above EMA 50
- SMA 200
- $32.26
- Price above SMA 200
- EMA 200
- $31.16
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
No data available
Source: third-party data provider
Latest news

IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
IMVT

IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
IMVT

IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
IMVT

Immunovant Q1 Earnings Call Highlights
Immunovant Q1 Earnings Call Highlights
IMVT

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
IMVT

Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
IMVT

Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
IMVT

IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
IMVT

IMVT Rockets 35% Despite Wider Loss As Arthritis Drug Shines In Study
IMVT Rockets 35% Despite Wider Loss As Arthritis Drug Shines In Study
IMVT

Immunovant Q4 Earnings Call Highlights
Immunovant Q4 Earnings Call Highlights
IMVT
News tone: automated (AI) classification of the article's content, not a price prediction.
About Immunovant, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Eric Venker M.D., Pharm.D. | CEO & Director | 1987 |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board | 1979 |
| Mr. Tiago M. Girao CPA | Chief Financial Officer | 1979 |
| Ms. Melanie Gloria B.S.N. | Chief Operating Officer | 1978 |
| Dr. Jay S. Stout M.S., Ph.D. | Chief Technology Officer | 1963 |
| Mr. Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer & Corporate Secretary | 1975 |
| Ms. Christine Blodgett | Senior Vice President of Human Resources | — |
| Ms. Becky Merlina | Senior VP & Global Head of Quality | — |
| Ms. Yan Zheng M.S., Ph.D. | Senior Vice President of Biostatistics, Programming & Data Management | — |
| Ms. Sheetal Patel M.B.A., M.D., M.S. | Senior Vice President of Clinical Development | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 70.54
- MACD 12/26/9
- 0.55
- EMA 9 of MACD
- -0.65
- MACD histogram
- 1.20
- SMA 50
- $32.83
- Price above SMA 50
- EMA 50
- $32.66
- Price above EMA 50
- SMA 200
- $32.26
- Price above SMA 200
- EMA 200
- $31.16
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $33.00
- Average
- $40.00
- High
- $47.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -5.9 | +13.1 | ||||||||||
| 2022 | -20.3 | -20.2 | +0.9 | -17.5 | -7.8 | -5.1 | +3.5 | +31.0 | +6.1 | +70.0 | +13.9 | +28.0 |
| 2023 | -5.2 | -4.0 | -11.4 | +4.1 | +19.2 | -8.3 | +21.8 | -1.6 | +60.0 | -4.6 | +16.9 | +3.9 |
| 2024 | -12.0 | -1.9 | -8.5 | -13.2 | -11.0 | +4.8 | +5.7 | +7.0 | -6.4 | +2.8 | -4.0 | -14.0 |
| 2025 | -13.7 | -1.0 | -7.3 | +6.2 | -6.6 | +3.8 | -0.4 | -6.5 | +7.0 | +51.0 | +1.6 | +11.7 |
| 2026 | +0.3 | +6.3 | -10.5 | +8.2 | +22.8 | +17.3 | +1.3 | +6.0 | -15.3 | -13.3 | +30.4 |



